Charles Schwab Investment Management Inc. Grows Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Charles Schwab Investment Management Inc. increased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 11.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,401,533 shares of the biotechnology company’s stock after acquiring an additional 249,412 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in ADMA Biologics were worth $48,007,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Quest Partners LLC purchased a new position in ADMA Biologics in the second quarter valued at about $29,000. Hollencrest Capital Management purchased a new position in ADMA Biologics in the third quarter worth $30,000. CWM LLC increased its position in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 4,367 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of ADMA Biologics in the 2nd quarter valued at approximately $93,000. Finally, USA Financial Formulas increased its position in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 539 shares during the period. Institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ADMA shares. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James boosted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Stock Down 7.9 %

Shares of ADMA Biologics stock opened at $20.11 on Monday. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $4.75 billion, a P/E ratio of 71.82 and a beta of 0.64. The company has a 50 day moving average of $19.08 and a 200 day moving average of $15.40.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the prior year, the company earned $0.01 earnings per share. As a group, research analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.